$PBYI
PUMA BIOTECHNOLOGY, INC.

2021 Q2 Form 10-Q Financial Statement

#000156459021041634 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $53.38M $70.58M $51.22M
YoY Change -24.37% 30.9% -48.3%
Cost Of Revenue $11.97M $9.420M $9.080M
YoY Change 27.06% 1.11% 13.64%
Gross Profit $41.42M $61.17M $42.14M
YoY Change -32.3% 37.15% -53.73%
Gross Profit Margin 77.58% 86.67% 82.28%
Selling, General & Admin $39.41M $29.35M $30.94M
YoY Change 34.29% -12.47% -32.02%
% of Gross Profit 95.16% 47.98% 73.41%
Research & Development $18.64M $24.69M $25.46M
YoY Change -24.52% -33.01% -28.75%
% of Gross Profit 45.0% 40.36% 60.41%
Depreciation & Amortization $200.0K $300.0K $200.0K
YoY Change -33.33% -85.71% 0.0%
% of Gross Profit 0.48% 0.49% 0.47%
Operating Expenses $70.02M $63.45M $65.47M
YoY Change 10.34% -20.38% -26.62%
Operating Profit -$16.63M $7.129M -$23.33M
YoY Change -333.31% -127.65% -336.88%
Interest Expense $3.518M $3.784M $3.068M
YoY Change -7.03% -14.93% -30.95%
% of Operating Profit 53.08%
Other Income/Expense, Net $11.57M -$3.734M -$2.682M
YoY Change -409.72% -67.93% -86.55%
Pretax Income -$5.068M $3.395M -$16.93M
YoY Change -249.28% -109.07% 67.82%
Income Tax $38.00K
% Of Pretax Income
Net Earnings -$5.106M $3.395M -$16.93M
YoY Change -250.4% -109.07% 67.87%
Net Earnings / Revenue -9.56% 4.81% -33.06%
Basic Earnings Per Share -$0.13 $0.09 -$0.43
Diluted Earnings Per Share -$0.13 $0.08 -$0.43
COMMON SHARES
Basic Shares Outstanding 40.48M 39.43M 39.29M
Diluted Shares Outstanding 40.48M 40.00M 39.29M

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $109.0M $107.3M $100.6M
YoY Change 1.56% -8.84% -33.11%
Cash & Equivalents $89.80M $90.90M $83.40M
Short-Term Investments $19.13M $16.40M $17.20M
Other Short-Term Assets $478.0K $3.426M $23.30M
YoY Change -86.05% 938.18% 129.44%
Inventory $7.620M $2.900M $3.300M
Prepaid Expenses
Receivables $26.08M $21.30M $27.00M
Other Receivables $4.467M $6.100M $4.500M
Total Short-Term Assets $167.8M $159.2M $158.7M
YoY Change 5.36% 1.02% -38.05%
LONG-TERM ASSETS
Property, Plant & Equipment $2.099M $2.859M $3.085M
YoY Change -26.58% -16.7% -17.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.768M $6.100M $6.300M
YoY Change -21.84% -61.15% -8.7%
Total Long-Term Assets $92.25M $104.6M $66.80M
YoY Change -11.8% 27.16% -11.17%
TOTAL ASSETS
Total Short-Term Assets $167.8M $159.2M $158.7M
Total Long-Term Assets $92.25M $104.6M $66.80M
Total Assets $260.0M $263.8M $225.5M
YoY Change -1.45% 9.99% -31.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.17M $11.77M $17.30M
YoY Change -5.11% -21.92% -40.09%
Accrued Expenses $66.99M $68.64M $69.46M
YoY Change -2.41% -7.56% -1.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $31.43M
YoY Change
Total Short-Term Liabilities $137.9M $94.53M $90.47M
YoY Change 45.89% 3.13% -10.78%
LONG-TERM LIABILITIES
Long-Term Debt $68.71M $96.60M $95.80M
YoY Change -28.88% 3.43% -37.3%
Other Long-Term Liabilities $23.92M $49.30M $29.90M
YoY Change -51.47% 49.39% -11.01%
Total Long-Term Liabilities $92.63M $145.9M $125.7M
YoY Change -36.51% 15.43% -32.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $137.9M $94.53M $90.47M
Total Long-Term Liabilities $92.63M $145.9M $125.7M
Total Liabilities $230.5M $240.4M $216.2M
YoY Change -4.11% 10.24% -24.92%
SHAREHOLDERS EQUITY
Retained Earnings -$1.291B -$1.295B
YoY Change 3.33%
Common Stock $1.315B $1.304B
YoY Change 3.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.47M $23.40M $9.377M
YoY Change
Total Liabilities & Shareholders Equity $260.0M $263.8M $225.5M
YoY Change -1.45% 9.99% -31.95%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$5.106M $3.395M -$16.93M
YoY Change -250.4% -109.07% 67.87%
Depreciation, Depletion And Amortization $200.0K $300.0K $200.0K
YoY Change -33.33% -85.71% 0.0%
Cash From Operating Activities -$73.00K $16.23M -$11.54M
YoY Change -100.45% -63.32% -28.46%
INVESTING ACTIVITIES
Capital Expenditures -$10.01M
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$5.732M $790.0K $34.38M
YoY Change -825.57% -92.95% -177.12%
Cash From Investing Activities -$5.732M -$9.220M $34.38M
YoY Change -37.83% -182.32% -177.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -73.00K 16.23M -11.54M
Cash From Investing Activities -5.732M -9.220M 34.38M
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -5.805M 7.010M 22.84M
YoY Change -182.81% -154.89% -138.3%
FREE CASH FLOW
Cash From Operating Activities -$73.00K $16.23M -$11.54M
Capital Expenditures -$10.01M
Free Cash Flow $26.24M
YoY Change -40.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M12D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M21D
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40086387
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40086387
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1337631000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-5951000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
244220000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70582000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
151553000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
121799000
CY2021Q2 pbyi Cost Of Sales
CostOfSales
11969000
CY2020Q2 pbyi Cost Of Sales
CostOfSales
9415000
pbyi Cost Of Sales
CostOfSales
41527000
pbyi Cost Of Sales
CostOfSales
18491000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
39410000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29347000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
67748000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
60284000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18638000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24691000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38866000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50146000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
70017000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
63453000
us-gaap Operating Expenses
OperatingExpenses
148141000
us-gaap Operating Expenses
OperatingExpenses
128921000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16633000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
7129000
us-gaap Operating Income Loss
OperatingIncomeLoss
3412000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7122000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
121000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
66000
us-gaap Investment Income Interest
InvestmentIncomeInterest
134000
us-gaap Investment Income Interest
InvestmentIncomeInterest
452000
CY2021Q2 us-gaap Interest Expense
InterestExpense
3518000
CY2020Q2 us-gaap Interest Expense
InterestExpense
3784000
us-gaap Interest Expense
InterestExpense
6968000
us-gaap Interest Expense
InterestExpense
6852000
CY2021Q2 pbyi Legal Verdict Expense Credit
LegalVerdictExpenseCredit
14902000
CY2020Q2 pbyi Legal Verdict Expense Credit
LegalVerdictExpenseCredit
-93000
pbyi Legal Verdict Expense Credit
LegalVerdictExpenseCredit
14717000
pbyi Legal Verdict Expense Credit
LegalVerdictExpenseCredit
-186000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
60000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
77000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
102000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
170000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11565000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3734000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7985000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6416000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5068000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3395000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11397000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13538000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
75000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
us-gaap Net Income Loss
NetIncomeLoss
-13538000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40479577
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39432030
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40370825
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39361596
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40479577
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39997571
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40939688
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39361596
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5106000
us-gaap Net Income Loss
NetIncomeLoss
11322000
us-gaap Net Income Loss
NetIncomeLoss
-13538000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-64000
CY2021Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2020Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-3000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5107000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3394000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
11321000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13599000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
16337000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18239000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5106000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
29469000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
9377000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10630000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2000
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
3395000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
23403000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000
us-gaap Net Income Loss
NetIncomeLoss
11322000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
29469000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
17463000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19537000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-3000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-64000
us-gaap Net Income Loss
NetIncomeLoss
-13538000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
23403000
us-gaap Profit Loss
ProfitLoss
11322000
us-gaap Profit Loss
ProfitLoss
-13538000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5886000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4153000
us-gaap Share Based Compensation
ShareBasedCompensation
24099000
us-gaap Share Based Compensation
ShareBasedCompensation
19537000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-1000000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4006000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4909000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4166000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-279000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-271000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
119000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-3163000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
3103000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-910000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7416000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-18503000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
155000
us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
44000
pbyi Increase Decrease In Post Marketing Commitment Liability
IncreaseDecreaseInPostMarketingCommitmentLiability
-569000
pbyi Increase Decrease In Post Marketing Commitment Liability
IncreaseDecreaseInPostMarketingCommitmentLiability
-125000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
15587000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4688000
pbyi Payments To Acquire Property Plant And Equipment Excluding Capital Improvements
PaymentsToAcquirePropertyPlantAndEquipmentExcludingCapitalImprovements
12000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
19117000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
16376000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
8085000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
51546000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11032000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
25158000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4555000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
29848000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
97454000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73210000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
102009000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
103058000
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
20000000
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
30000000
us-gaap Interest Paid Net
InterestPaidNet
4550000
us-gaap Interest Paid Net
InterestPaidNet
4721000
us-gaap Income Taxes Paid
IncomeTaxesPaid
84000
pbyi Number Of Subsidiaries
NumberOfSubsidiaries
2
us-gaap Net Income Loss
NetIncomeLoss
11300000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
15600000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
89800000
CY2021Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19100000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates: </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of revenues and expenses for the period presented. Accordingly, actual results could differ from those estimates. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products. </p>
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9434076000
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8337364000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8048926000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9605509000
us-gaap Net Income Loss
NetIncomeLoss
-13538000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39362000
CY2020Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
566000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
569000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40940000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39362000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2021Q2 pbyi Incremental Costs Expenses
IncrementalCostsExpenses
0
CY2020Q2 pbyi Incremental Costs Expenses
IncrementalCostsExpenses
0
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
12200000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
12200000
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
79831000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
79830000
CY2020 pbyi Available For Sale Securities Maturity
AvailableForSaleSecuritiesMaturity
Less than 1
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
79813000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
79813000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents, marketable securities, and accounts receivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at June 30, 2021, were approximately $102.0 million. The Company does not believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-1/P-1 or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its accounts receivables, net and product revenues, net. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on the credit worthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. The Company recorded a recovery of $1.0 million credit loss and $1.0 million as an allowance for credit loss for the periods ended June 30, 2021 and December 31, 2020, respectively.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product and limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future.  </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company relies exclusively on third parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company has no experience in drug formulation or manufacturing and does not intend to establish its own manufacturing facilities. The Company lacks the resources and expertise to formulate or manufacture NERLYNX and other drug candidates. While the drug candidates were being developed by Pfizer, both the drug substance and drug product were manufactured by third-party contractors. The Company is using the same third-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX. If the Company is unable to continue its relationships with one or more of these third-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third-party contractors to manufacture the commercial supply of drugs.</span></p>
CY2021Q2 pbyi Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits
CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits
102000000.0
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-1000000.0
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1000000.0
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.
us-gaap Lessee Operating Lease Option To Terminate
LesseeOperatingLeaseOptionToTerminate
Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.
CY2021Q2 pbyi Average Incremental Borrowing Rate
AverageIncrementalBorrowingRate
0.109
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
4000000.0
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2000000.0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4000000.0
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
8000000.0
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
8000000.0
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
8000000.0
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
8000000.0
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
8000000.0
CY2021Q2 pbyi Finite Lived Intangible Assets Amortization Expense Year Six
FiniteLivedIntangibleAssetsAmortizationExpenseYearSix
8000000.0
CY2021Q2 pbyi Finite Lived Intangible Assets Amortization Expense Year Seven
FiniteLivedIntangibleAssetsAmortizationExpenseYearSeven
8000000.0
CY2021Q2 pbyi Finite Lived Intangible Assets Amortization Expense Year Eight
FiniteLivedIntangibleAssetsAmortizationExpenseYearEight
8000000.0
CY2021Q2 pbyi Finite Lived Intangible Assets Amortization Expense Year Nine
FiniteLivedIntangibleAssetsAmortizationExpenseYearNine
2000000.0
CY2021Q2 pbyi Trade Accounts Receivable Net Excluding License Revenue Receivable
TradeAccountsReceivableNetExcludingLicenseRevenueReceivable
26082000
CY2020Q4 pbyi Trade Accounts Receivable Net Excluding License Revenue Receivable
TradeAccountsReceivableNetExcludingLicenseRevenueReceivable
21515000
CY2021Q2 pbyi License Revenue Receivable
LicenseRevenueReceivable
250000
CY2020Q4 pbyi License Revenue Receivable
LicenseRevenueReceivable
2500000
CY2021Q2 pbyi Royalty Revenue Receivable
RoyaltyRevenueReceivable
4217000
CY2020Q4 pbyi Royalty Revenue Receivable
RoyaltyRevenueReceivable
2528000
CY2021Q2 us-gaap Accounts Receivable Gross
AccountsReceivableGross
30549000
CY2020Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
26543000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1000000
CY2021Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
30549000
CY2020Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
25543000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-1000000.0
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1000000.0
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1000000
us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
1000000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11262000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
1745000
CY2020Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
13007000
CY2020Q4 pbyi Deposit For Manufacturing Costs Current
DepositForManufacturingCostsCurrent
3376000
CY2021Q2 us-gaap Deferred Rent Asset Net Current
DeferredRentAssetNetCurrent
197000
CY2020Q4 us-gaap Deferred Rent Asset Net Current
DeferredRentAssetNetCurrent
198000
CY2021Q2 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
281000
CY2020Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
67000
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
478000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3641000
pbyi Fixed Lease Expense
FixedLeaseExpense
2300000
us-gaap Variable Lease Cost
VariableLeaseCost
200000
us-gaap Operating Lease Payments
OperatingLeasePayments
2845000
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.109
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2704000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5483000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5631000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5805000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5983000
CY2021Q2 pbyi Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1508000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
27114000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5955000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
21159000
CY2021Q2 us-gaap Sublease Income
SubleaseIncome
100000
CY2021Q2 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
236000
CY2021Q2 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
481000
CY2021Q2 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
495000
CY2021Q2 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
510000
CY2021Q2 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
525000
CY2021Q2 pbyi Lessor Operating Lease Payments To Be Received After Year Four
LessorOperatingLeasePaymentsToBeReceivedAfterYearFour
134000
CY2021Q2 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
2381000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8630000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6531000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2099000
CY2021Q2 us-gaap Depreciation
Depreciation
200000
CY2021Q2 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
90000000
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19867000
CY2021Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
70133000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2000000.0
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P8Y9M18D
CY2021Q2 pbyi Accrued Legal Verdict Expense Current
AccruedLegalVerdictExpenseCurrent
32829000
CY2021Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
9345000
CY2021Q2 pbyi Accrued Development Costs
AccruedDevelopmentCosts
2854000
CY2021Q2 pbyi Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
8307000
CY2021Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3551000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4704000
CY2021Q2 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
2037000
CY2021Q2 pbyi Accrued Professional Fees Liability Current
AccruedProfessionalFeesLiabilityCurrent
1321000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
878000
CY2021Q2 pbyi Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
429000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
733000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
66988000
CY2020Q4 pbyi Accrued Legal Verdict Expense Non Current
AccruedLegalVerdictExpenseNonCurrent
24822000
CY2021Q2 pbyi Accrued Clinical Research Organization Services Noncurrent
AccruedClinicalResearchOrganizationServicesNoncurrent
971000
CY2020Q4 pbyi Accrued Clinical Research Organization Services Noncurrent
AccruedClinicalResearchOrganizationServicesNoncurrent
908000
CY2021Q2 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
206000
CY2020Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
233000
CY2021Q2 pbyi Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
1177000
CY2020Q4 pbyi Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
25963000
CY2021Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
68165000
CY2020Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
87288000
CY2021Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
100000000
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2024-06-01
CY2021Q2 pbyi Accretion Of Final Interest Payment
AccretionOfFinalInterestPayment
4051000
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
31429000
CY2021Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
3916000
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
68706000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q2 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
8668000
CY2020Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
8668000
CY2021Q2 us-gaap Accumulated Amortization Deferred Finance Costs
AccumulatedAmortizationDeferredFinanceCosts
4752000
CY2020Q4 us-gaap Accumulated Amortization Deferred Finance Costs
AccumulatedAmortizationDeferredFinanceCosts
3666000
CY2021Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
3916000
CY2020Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
5002000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1100000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
900000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
647541
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
423113
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2021-10-04
CY2021Q2 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2026-10-04
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.870
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.008
CY2021Q2 pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
18239000
CY2020Q2 pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
10630000
pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
24099000
pbyi Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
19537000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5009342
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
71.42
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3458000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
532027
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
110183
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
189439
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
117.98
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5241747
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
64.91
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2528000
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
985497
CY2021Q2 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice
10.93
CY2021Q2 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue
388000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4256250
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
77.41
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2140000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.32
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.86
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
899672
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
8.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
532027
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
110183
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
12.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
336019
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
9.65
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
985497
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
8.11
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1000000.0
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
700000
CY2021Q2 pbyi Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
187500000
pbyi Percentage Of Unpaid Portion Of Milestone Payments Interest Rate
PercentageOfUnpaidPortionOfMilestonePaymentsInterestRate
0.0625

Files In Submission

Name View Source Status
0001564590-21-041634-index-headers.html Edgar Link pending
0001564590-21-041634-index.html Edgar Link pending
0001564590-21-041634.txt Edgar Link pending
0001564590-21-041634-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pbyi-10q_20210630.htm Edgar Link pending
pbyi-10q_20210630_htm.xml Edgar Link completed
pbyi-20210630.xsd Edgar Link pending
pbyi-20210630_cal.xml Edgar Link unprocessable
pbyi-20210630_def.xml Edgar Link unprocessable
pbyi-20210630_lab.xml Edgar Link unprocessable
pbyi-20210630_pre.xml Edgar Link unprocessable
pbyi-ex311_6.htm Edgar Link pending
pbyi-ex312_12.htm Edgar Link pending
pbyi-ex321_11.htm Edgar Link pending
pbyi-ex322_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending